Cogent Biosciences Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT) announced its participation in two upcoming investor conferences in February 2023. Andrew Robbins, President and CEO, will present at the Guggenheim Healthcare Talks Idea Forum Oncology Day on February 8 at 10:10 a.m. ET, and the SVB Securities Global Biopharma Conference on February 14 at 9:20 a.m. ET. Interested investors can access live webcasts of these events on the Investors & Media page of Cogent's website, with replays available for 30 days post-event. Cogent focuses on precision therapies for genetically defined diseases, including bezuclastinib for systemic mastocytosis and advanced gastrointestinal stromal tumors.

WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will participate in the following upcoming investor conferences in February:

• Guggenheim Healthcare Talks Idea Forum Oncology Day
  Date/Time: Wednesday, February 8, 2023 at 10:10 a.m. ET
  

• SVB Securities Global Biopharma Conference:
  Date/Time: Tuesday, February 14, 2023 at 9:20 a.m. ET
  

A live webcast of each event can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 30 days.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

What investor conferences will Cogent Biosciences participate in February 2023?

Cogent Biosciences will participate in the Guggenheim Healthcare Talks Idea Forum Oncology Day on February 8, 2023, and the SVB Securities Global Biopharma Conference on February 14, 2023.

What is the date and time for the Guggenheim Healthcare Talks Idea Forum?

The Guggenheim Healthcare Talks Idea Forum Oncology Day is scheduled for February 8, 2023, at 10:10 a.m. ET.

When will Cogent Biosciences present at the SVB Securities Global Biopharma Conference?

Cogent Biosciences will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 a.m. ET.

Where can I watch Cogent Biosciences' investor conference webcasts?

Webcasts of Cogent Biosciences' investor conferences can be accessed on the Investors & Media page of their website.

What is bezuclastinib and its significance to Cogent Biosciences?

Bezuclastinib is a selective tyrosine kinase inhibitor being developed by Cogent Biosciences to target the KIT D816V mutation, which is linked to systemic mastocytosis and certain gastrointestinal cancers.